AlphaSense's Kate Thunnissen and Chris Ackerson discuss augmented intelligence and its impact on Investor Relations workflows.
AlphaSense Staff
At the BIO CEO & Investor Conference 2019, AlphaSense discusses the shifting M&A landscape following a record-setting year of biotech IPOs.
{{ post.author.name }} {{ post.author.title }}
{{ post.intro }}